Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$171.32 USD

171.32
2,298,772

-4.53 (-2.58%)

Updated Jun 13, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth???s Hospitality

by Zacks Equity Research

Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth???s Hospitality

Zoetis (ZTS) Up 0.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth's Hospitality

by Zacks Equity Research

Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth's Hospitality

4 GARP Stocks to Scoop Up for Maximum Returns

by Zacks Equity Research

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio

by Zacks Equity Research

Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.

Is Zoetis (ZTS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ZTS) Outperforming Other Medical Stocks This Year?

Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence Design System

by Zacks Equity Research

Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence Design System

4 GARP Stocks for a Winning Portfolio

by Zacks Equity Research

Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

Sweta Killa headshot

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for FTCS

JAZZ or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales

by Zacks Equity Research

Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.

Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 5.62% and 0.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.

Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence

by Zacks Equity Research

Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence

Zoetis (ZTS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Zoetis (ZTS) closed at $127.92, marking a +0.25% move from the previous day.

Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 GARP Stocks to Scoop Up for Maximum Returns

by Zacks Equity Research

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ZTS) Outperforming Other Medical Stocks This Year?

5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

3 Reasons Why Zoetis (ZTS) Is a Great Growth Stock

by Zacks Equity Research

Zoetis (ZTS) could produce exceptional returns because of its solid growth attributes.

Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ZTS) Outperforming Other Medical Stocks This Year?

Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.